Jump to content

Heparin-binding EGF-like growth factor

From Wikipedia, the free encyclopedia
(Redirected from Dtsf)
HBEGF
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesHBEGF, DTR, DTS, DTSF, HEGFL, heparin binding EGF like growth factor
External IDsOMIM: 126150; MGI: 96070; HomoloGene: 1466; GeneCards: HBEGF; OMA:HBEGF - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1839

15200

Ensembl

ENSG00000113070

ENSMUSG00000024486

UniProt

Q99075

Q06186

RefSeq (mRNA)

NM_001945

NM_010415

RefSeq (protein)

NP_001936

NP_034545

Location (UCSC)Chr 5: 140.33 – 140.35 MbChr 18: 36.64 – 36.65 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF family of proteins that in humans is encoded by the HBEGF gene.

HB-EGF-like growth factor is synthesized as a membrane-anchored mitogenic and chemotactic glycoprotein. An epidermal growth factor produced by monocytes and macrophages, due to an affinity for heparin is termed HB-EGF. It has been shown to play a role in wound healing, cardiac hypertrophy, and heart development and function.[5] First identified in the conditioned media of human macrophage-like cells, HB-EGF is an 87-amino acid glycoprotein that displays highly regulated gene expression.[6] Ectodomain shedding results in the soluble mature form of HB-EGF, which influences the mitogenicity and chemotactic factors for smooth muscle cells and fibroblasts. The transmembrane form of HB-EGF is the unique receptor for diphtheria toxin and functions in juxtacrine signaling in cells. Both forms of HB-EGF participate in normal physiological processes and in pathological processes including tumor progression and metastasis, organ hyperplasia, and atherosclerotic disease.[7] HB-EGF can bind two locations on cell surfaces: heparan sulfate proteoglycans and EGF-receptors effecting cell-to-cell interactions.[8]

Interactions

[edit]

Heparin-binding EGF-like growth factor has been shown to interact with NRD1,[9] Zinc finger and BTB domain-containing protein 16[10][11] and BAG1.[12]

HB-EGF biological activities with these genes influence cell cycle progression, molecular chaperone regulation, cell survival, cellular functions, adhesion, and mediation of cell migration. The NRD1 gene codes for the protein nardilysin, an HB-EGF modulator.[13] Zinc finger and BTB domain-containing protein 16 and BAG family molecular chaperone regulator function as co-chaperone proteins in processes involving HB-EGF.

Role in cancer

[edit]

Recent studies indicate significant HB-EGF gene expression elevation in a number of human cancers as well as cancer-derived cell lines. Evidence indicates that HB-EGF plays a significant role in the development of malignant phenotypes contributing to the metastatic and invasive behaviors of tumors.[14] The proliferative and chemotactic effects of HB-EGF results from the target influence on particular cells including fibroblasts, smooth muscles cells, and keratinocytes. For numerous cell types such as breast and ovarian tumor cells, human epithelial cells and keratinocytes HB-EGF is a potent mitogen resulting in evidenced upregulation of HB-EGF in such specimens.[15] Both in vivo and in vitro studies of tumor formation in cancer derived cell lines indicate that expression of HB-EGF is essential for tumor development. As a result, studies implementing the use of specific HB-EGF inhibitors and monoclonal antibodies against HB-EGF show the potential for the development of novel therapies for treating cancers by targeting HB-EGF expression.[16]

Role in cardiac development and vasculature

[edit]

HB-EGF binding and activation of EGF receptors plays a critical role during cardiac valve tissue development and the maintenance of normal heart function in adults. During valve tissue development the interaction of HB-EGF with EGF receptors and heparan sulfate proteoglycans is essential for the prevention of malformation of valves due to enlargement.[17] In the vascular system areas of disturbed flow show upregulation of HB-EGF with promotion of vascular lesions, atherogenesis, and hyperplasia of intimal tissue in vessels. The flow disturbance remodeling of the vascular tissues due to HB-EGF expression contributes to aortic valve disease, peripheral vascular disease, and conduit stenosis.[18]

Role in wound healing

[edit]

HB-EGF is the predominant growth factor in the epithelialization required for cutaneous wound healing. The mitogenic and migratory effects of HB-EGF on keratinocytes and fibroblasts promotes dermal repair and angiogenesis necessary for wound healing and is a major component of wound fluids.[19] HB-EGF displays target cell specificity during the early stages of wound healing being released by macrophages, monocytes, and keratinocytes. HB-EGF cell surface binding to heparan sulfate proteoglycans enhances mitogen promoting capabilities increasing the rate of skin wound healing, decreasing human skin graft healing times, and promotes rapid healing of ulcers, burns, and epidermal split thickness wounds.[20]

Role in other physiological processes

[edit]

HB-EGF is recognized as an important component for the modulation of cell activity in various biological interactions. Found widely distributed in cerebral neurons and neuroglia, HB-EGF induced by brain hypoxia and or ischemia subsequently stimulates neurogenesis.[6] Interactions between uterine HB-EGF and epidermal growth factor receptors of blastocysts influence embryo-uterine interactions and implantation.[21] Studies show HB-EGF protects intestinal stem cells and intestinal epithelial cells in necrotizing enterocolitis, a disease affecting premature newborns. Associated with a breakdown in gut barrier function, necrotizing enterocolitis may be mediated by HB-EGF effects on intestinal mucosa.[22] HB-EGF expressed during skeletal muscle contraction facilitates peripheral glucose removal, glucose tolerance and uptake. The upregulation of HB-EGF with exercise may explain the molecular basis for the decrease in metabolic disorders such as obesity and type 2 diabetes with regular exercise.[23]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000113070 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000024486 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Nanba D, Higashiyama S (February 2004). "Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor". Cytokine Growth Factor Rev. 15 (1): 13–9. doi:10.1016/j.cytogfr.2003.10.002. PMID 14746810.
  6. ^ a b Jin K, Mao XO, Sun Y, Xie L, Jin L, Nishi E, Klagsbrun M, Greenberg DA (July 2002). "Heparin-binding epidermal growth factor-like growth factor: hypoxia-inducible expression in vitro and stimulation of neurogenesis in vitro and in vivo". J. Neurosci. 22 (13): 5365–73. doi:10.1523/JNEUROSCI.22-13-05365.2002. PMC 6758221. PMID 12097488.
  7. ^ Raab G, Klagsbrun M (December 1997). "Heparin-binding EGF-like growth factor". Biochim. Biophys. Acta. 1333 (3): F179–99. doi:10.1016/S0304-419X(97)00024-3. PMID 9426203.
  8. ^ Das SK, Wang XN, Paria BC, Damm D, Abraham JA, Klagsbrun M, Andrews GK, Dey SK (May 1994). "Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: a possible ligand for interaction with blastocyst EGF-receptor in implantation". Development. 120 (5): 1071–83. doi:10.1242/dev.120.5.1071. PMID 8026321.
  9. ^ Nishi E, Prat A, Hospital V, Elenius K, Klagsbrun M (July 2001). "N-arginine dibasic convertase is a specific receptor for heparin-binding EGF-like growth factor that mediates cell migration". EMBO J. 20 (13): 3342–50. doi:10.1093/emboj/20.13.3342. PMC 125525. PMID 11432822.
  10. ^ Nanba D, Mammoto A, Hashimoto K, Higashiyama S (November 2003). "Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF". J. Cell Biol. 163 (3): 489–502. doi:10.1083/jcb.200303017. PMC 2173632. PMID 14597771.
  11. ^ Nanba D, Toki F, Higashiyama S (July 2004). "Roles of charged amino acid residues in the cytoplasmic domain of proHB-EGF". Biochem. Biophys. Res. Commun. 320 (2): 376–82. doi:10.1016/j.bbrc.2004.05.176. PMID 15219838.
  12. ^ Lin J, Hutchinson L, Gaston SM, Raab G, Freeman MR (August 2001). "BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation". J. Biol. Chem. 276 (32): 30127–32. doi:10.1074/jbc.M010237200. PMID 11340068.
  13. ^ Hospital V, Prat A (October 2004). "Nardilysin, a basic residues specific metallopeptidase that mediates cell migration and proliferation". Protein Pept. Lett. 11 (5): 501–8. doi:10.2174/0929866043406508. PMID 15544571.
  14. ^ Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E (May 2006). "Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy". Cancer Sci. 97 (5): 341–7. doi:10.1111/j.1349-7006.2006.00188.x. PMC 11159358. PMID 16630129. S2CID 32160328.
  15. ^ Nolan TM, Di Girolamo N, Coroneo MT, Wakefield D (January 2004). "Proliferative effects of heparin-binding epidermal growth factor-like growth factor on pterygium epithelial cells and fibroblasts". Invest. Ophthalmol. Vis. Sci. 45 (1): 110–3. doi:10.1167/iovs.03-0046. PMID 14691161.
  16. ^ Miyazono K (January 2012). "Ectodomain shedding of HB-EGF: a potential target for cancer therapy". J. Biochem. 151 (1): 1–3. doi:10.1093/jb/mvr120. PMID 21976708.
  17. ^ Iwamoto R, Mekada E (2006). "ErbB and HB-EGF signaling in heart development and function". Cell Struct. Funct. 31 (1): 1–14. doi:10.1247/csf.31.1. PMID 16508205.
  18. ^ Zhang H, Sunnarborg SW, McNaughton KK, Johns TG, Lee DC, Faber JE (May 2008). "Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling". Circ. Res. 102 (10): 1275–85. doi:10.1161/CIRCRESAHA.108.171728. PMC 2752633. PMID 18436796.
  19. ^ Shirakata Y, Kimura R, Nanba D, Iwamoto R, Tokumaru S, Morimoto C, Yokota K, Nakamura M, Sayama K, Mekada E, Higashiyama S, Hashimoto K (June 2005). "Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing". J. Cell Sci. 118 (Pt 11): 2363–70. doi:10.1242/jcs.02346. PMID 15923649. S2CID 17496049.
  20. ^ Marikovsky M, Breuing K, Liu PY, Eriksson E, Higashiyama S, Farber P, Abraham J, Klagsbrun M (May 1993). "Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury". Proc. Natl. Acad. Sci. U.S.A. 90 (9): 3889–93. Bibcode:1993PNAS...90.3889M. doi:10.1073/pnas.90.9.3889. PMC 46411. PMID 8483908.
  21. ^ Leach RE, Khalifa R, Armant DR, Brudney A, Das SK, Dey SK, Fazleabas AT (September 2001). "Heparin-binding EGF-like growth factor modulation by antiprogestin and CG in the baboon (Papio anubis)". J. Clin. Endocrinol. Metab. 86 (9): 4520–8. doi:10.1210/jcem.86.9.7835. PMID 11549702.
  22. ^ Chen CL, Yu X, James IO, Zhang HY, Yang J, Radulescu A, Zhou Y, Besner GE (March 2012). "Heparin-binding EGF-like growth factor protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis". Lab. Invest. 92 (3): 331–44. doi:10.1038/labinvest.2011.167. PMC 3289750. PMID 22157721.
  23. ^ Fukatsu Y, Noguchi T, Hosooka T, Ogura T, Kotani K, Abe T, Shibakusa T, Inoue K, Sakai M, Tobimatsu K, Inagaki K, Yoshioka T, Matsuo M, Nakae J, Matsuki Y, Hiramatsu R, Kaku K, Okamura H, Fushiki T, Kasuga M (June 2009). "Muscle-specific overexpression of heparin-binding epidermal growth factor-like growth factor increases peripheral glucose disposal and insulin sensitivity". Endocrinology. 150 (6): 2683–91. doi:10.1210/en.2008-1647. PMID 19264873.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Heparin-binding_EGF-like_growth_factor&oldid=1235841848"